Table 3.
Characteristics of included studies
| Author | Year | Number of patients | Study design | Statin | Follow-up duration |
|---|---|---|---|---|---|
| Abraldes, et al | 2009 | 55 | Randomized controlled trial | simvastatin | 1 month |
| Kumar, et al | 2014 | 243 | Propensity Score Matching Case-control Study | atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin | 13 years |
| Simon, et al | 2015 | 543 | Cohort study | non-selected | 3.5 years |
| Yang, et al | 2015 | 84,213 | Propensity Score Matching Case-control Study | Non-selected | 4 years |
| Pollo-Flores, et al | 2015 | 34 | Randomized controlled trial | simvastatin | 3 months |
| Huang, et al | 2016 | 13,086 | Propensity Score Matching Case-control Study | non-selected | 12 years |
| Mohanty, et al | 2016 | 1370 | Propensity Score Matching Case-control Study | atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin | 14 years |
| Simon, et al | 2016 | 9135 | Case-control Study | atorvastatin and fluvastatin | 14 years |
| Abraldes, et al | 2016 | 147 | Randomized controlled trial | simvastatin | 2 years |
| Bang, et al | 2017 | 744 | Case-control Study | non-selected | 8 years |
| Chang, et al | 2017 | 1350 | Propensity Score Matching Case-control Study | non-selected | 8.5 years |
| Kim, et al | 2017 | 9852 | Nested Case-control Study | atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin | 12 years |
| Wong, et al | 2017 | 69,184 | Propensity Score Matching Case-control Study | atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin | 3 years |
| Wani, et al | 2017 | 76 | Self-control Study (Prospective Cohort) | simvastatin | 3 months |
| Bishnu, et al | 2018 | 23 | Randomized controlled trial | atorvastatin | 1 month |
| Kaplan, et al | 2019 | 19,341 | Propensity Score Matching Case-control Study | non-selected | 5.5 years |
| Elwan, et al | 2019 | 40 | Randomized controlled trial | simvastatin | 1 month |